Thirteen patients were not receiving antiretroviral therapy and 37 patients were on protocol-allowed medications (tenofovir, emtricitabine, rilpivirine,
raltegravir, and efavirenz). Although the inclusion criteria for patients receiving antiretroviral therapy allowed CD4+ T cell counts of greater than 100/µL, the median CD4+ T cell count was 576/µL.
Overall, 98% achieved sustained virologic response at 12 weeks (SVR12; 13/13 in treatment-naive arm and 36/37 in treatment-experienced arm).